CGON Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CG Oncology Inc (CGON) is not a strong buy at the moment for a beginner investor with a long-term focus. While the stock has strong analyst support and potential catalysts in its pipeline, the technical indicators and insider selling trends suggest caution. The lack of recent positive news and the mixed financial performance further reinforce a hold recommendation.
The MACD is negatively expanding, indicating bearish momentum. RSI is neutral at 39.282, and the stock price is below the pivot level of 67.609, suggesting weakness. However, moving averages are bullish (SMA_5 > SMA_20 > SMA_200), which provides some support for a longer-term uptrend.
Strong analyst support with multiple buy ratings and increased price targets. Potential for significant clinical and commercial opportunity with the Phase 3 PIVOT-006 trial. Revenue growth of 409.21% YoY in the latest quarter.
Insider selling has increased by 1311.54% over the last month. Gross margin has dropped significantly (-132.21% YoY), and net income remains negative. No recent news or congress trading data to support positive sentiment.
In Q4 2025, revenue increased by 409.21% YoY, net income improved by 29.91% YoY but remains negative at -$41.31M. EPS improved by 13.04% YoY to -0.52. However, gross margin dropped significantly to -32.21%, indicating operational inefficiencies.
Analysts are bullish with multiple buy ratings and increased price targets ranging from $75 to $100. The stock is seen as having room to run, driven by its Phase 3 PIVOT-006 trial and potential market share gains in the NMIBC treatment space.
